Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach

Reinbolt, Raquel E.; Mangini, Neha; Hill, Jordan; Levine, Lauren; Dempsey, Jessica; Singaravelu, Janani; Koehler, Kevin; Talley, Allison; Lustberg, Maryam B.

doi:10.1016/j.soncn.2015.02.002

Cited by 46 publications

(44 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…82,83 Currently, ERα antagonists such as TAM are widely used in clinical settings with great success. 117 Nevertheless, endocrine resistance remains partially responsible for patient relapse. [53][54][55] TAM is structurally similar to estrogen and competitively combines with ERs, subsequently blocking the entry of estrogen into tumor cells and inhibiting the development of cancers.…”

Section: Discussionmentioning

confidence: 99%

<p>ERα, A Key Target for Cancer Therapy: A Review</p>

Liu

Yao

2020

OTT

View full text Add to dashboard Cite

Estrogen receptor α (ERα) is closely associated with both hormone-dependent and hormone-independent tumors, and it is also essential for the development of these cancers. The functions of ERα are bi-faceted; it can contribute to cancer progression as well as cancer inhibition. Therefore, understanding ERα is vital for the treatment of those cancers that are closely associated with its expression. Here, we will elaborate on ERα based on its structure, localization, activation, modification, and mutation. Also, we will look at coactivators of ERα, elucidate the signaling pathway activated by ERα, and identify cancers related to its activation. A comprehensive understanding of ERα could help us to find new ways to treat cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>ERα, A Key Target for Cancer Therapy: A Review</p>

Liu

Yao

2020

OTT

View full text Add to dashboard Cite

show abstract

“…Since sex hormone signaling pathways play essential roles in cancer pathophysiology; the therapies targeting the hormones and their receptors, or endocrine therapies, are the mainstays of breast and prostate cancer treatment [22][23][24][25][26][27][28][29]. For breast cancer treatment, drugs that suppress estrogen signaling or estrogen production were used for endocrine therapies.…”

Section: Hormone-related Cancersmentioning

confidence: 99%

Roles of Splicing Factors in Hormone-Related Cancer Progression

Takeiwa

Mitobe

Ikeda

et al. 2020

IJMS

View full text Add to dashboard Cite

Splicing of mRNA precursor (pre-mRNA) is a mechanism to generate multiple mRNA isoforms from a single pre-mRNA, and it plays an essential role in a variety of biological phenomena and diseases such as cancers. Previous studies have demonstrated that cancer-specific splicing events are involved in various aspects of cancers such as proliferation, migration and response to hormones, suggesting that splicing-targeting therapy can be promising as a new strategy for cancer treatment. In this review, we focus on the splicing regulation by RNA-binding proteins including Drosophila behavior/human splicing (DBHS) family proteins, serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) in hormone-related cancers, such as breast and prostate cancers.

show abstract

“…A hormonioterapia, também chamada de terapia endócrina ou hormonal, é um tratamento com função de inibir a atividade doshormônios que tenham alguma influência no crescimento de um tumor. É usada no tratamento do câncer de mama e de próstata, que estão relacionados a distúrbios hormonais e, portanto, podem ser controlados por meio de inibidores dehormônios ou até mesmo por hormônios que neutralizem efeitos de outros hormônios.A administração dos medicamentos é realizada, principalmente, por via oral (BURSTEIN et al, 2014;REINBOLT et al, 2015) Assim como a quimioterapia, a terapia hormonal é uma forma de tratamento sistêmico, pois atinge células tumorais em todo o corpo e não apenas na mama. A principal função deste tipo de tratamento é inibir os receptores de estrogênio (RE) e de progesterona (RP).Cerca de 2/3 dos cânceres de mama são receptores hormonais positivos e altos níveis de Nascimento et al, (2019) estrogênio para esses cânceresestimulam as células tumoraisa crescerem e se disseminarem (AMERICAN CANCER SOCIETY, 2017c;BURSTEIN et al, 2014) São duas as principais formas de atuação da maioria dos tipos de terapia hormonal para câncer de mama.…”

Section: Hormonioterapiaunclassified

Principais Tratamentos Utilizados No Combate Ao Câncer De Mama: Uma Revisão De Literatura

Nascimento

Mello²,

Schneider³

et al. 2019

Arq Mudi

View full text Add to dashboard Cite

Resumo O câncer de mama é o mais frequente diagnóstico de câncer entre mulheres. Muito progresso tem sido alcançado nos últimos anos em relação ao tratamento, com diagnósticos cada vez mais precoces e precisos. O principal tratamento é a cirurgia, porém tratamentos adjuvantes como a quimioterapia, radioterapia, terapia hormonal e a imunoterapia reduzem o risco de recidiva do câncer de mama e o risco de morte por essa doença. Geralmente, estas terapias são indicadas após a cirurgia, como um complemento ao tratamento. Este trabalho tem como objetivo apresentar uma revisão de literatura sobre os principais métodos de tratamento do câncer de mama, suas implicações e resultados.

show abstract

Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach

Cited by 46 publications

References 45 publications

<p>ERα, A Key Target for Cancer Therapy: A Review</p>

<p>ERα, A Key Target for Cancer Therapy: A Review</p>

Roles of Splicing Factors in Hormone-Related Cancer Progression

Principais Tratamentos Utilizados No Combate Ao Câncer De Mama: Uma Revisão De Literatura

Contact Info

Product

Resources

About